UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

KINTARA THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Kintara Therapeutics, Inc. (the “Company”) previously designated (a) 5,000,000 shares of preferred stock as Special Voting Preferred Stock (the “Special Voting Preferred Stock”) and (b) 1,000,000 shares of preferred stock as Series B Preferred Stock (the “Series B Preferred Stock”).

The Company filed Withdrawals of Designation relating to the Special Voting Preferred Stock and the Series B Preferred Stock with the Secretary of State of Nevada and terminated the designation of its Special Voting Preferred Stock on July 12, 2024 and Series B Preferred Stock on July 12, 2024. At the time of the filing of the Withdrawals of Designation, no shares of any of the previously designated Special Voting Preferred Stock and Series B Preferred Stock were outstanding. The Withdrawals of Designation were effective upon filing, and eliminated from the Company’s Articles of Incorporation all matters set forth in the previously-filed Certificates of Designation with respect to the previously designated Special Voting Preferred Stock and Series B Preferred Stock.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.